Compares blood-thinning drug options after heart valve repair in people needing anticoagulants
Compares rivaroxaban alone with rivaroxaban plus clopidogrel in people with mitral regurgitation.
Plain-language title generated from the registry record
Registry title: STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
Where in China
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT06901466
- Record updated
- 9 March 2026
- Original description
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique.Studies have shown that patients with severe mitral regurgitation exhibit a high prevalence of atrial fibrillation (AF), reaching up to 63%, which is an indication for long-term oral anticoagulation (OAC) therapy. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients with an indication for OAC. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients who have an indication for OAC.Read full original descriptionShow less
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients With an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique.Studies have shown that patients with severe mitral regurgitation exhibit a high prevalence of atrial fibrillation (AF), reaching up to 63%, which is an indication for long-term oral anticoagulation (OAC) therapy. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients with an indication for OAC. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients who have an indication for OAC.
Inclusion: Successful TEER procedure, defined as technical success per MVARC criteria; Indication for long-term OAC; Ability and willingness to comply with the trial protocol; Provision of written informed consent; Women of childbearing potential must use effective contraception from the time of consent until the final dose of antithrombotic therapy; Antithrombotic strategy approved by the investigator.
Exclusion: Participation in another investigational drug or device study within 30 days; Absolute indication for anticoagulation in combination with antiplatelet therapy (eg, recent PCI); Recent ( < 12 month) intracranial or intracerebral hemorrhage; Recent ( < 12 month) gastrointestinal ulcers or hemorrhage; Hepatic disease with coagulopathy.(eg, Child-Pugh class B or C cirrhosis); Allergy, intolerance, or contraindication to research drugs; History of stroke or TIA within the past 6 weeks; Severe renal impairment (creatinine clearance < 15 mL/min or requiring dialysis); Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g/dL drop in hemoglobin or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure; Platelet count < 50 × 10\^9 /L; Need for reoperation due to complications of the index TEER procedure; Life expectancy < 12 months; Pregnancy or breastfeeding.